Peginterferon Alpha-2b Therapy in Chronic Hepatitis Patients With Normal ALT Level and Low Viremia

  • STATUS
    Recruiting
  • End date
    Dec 10, 2023
  • participants needed
    300
  • sponsor
    Fuzhou General Hospital
Updated on 23 March 2022

Summary

To date, antiviral treatment is not recommended for chronic hepatitis B patients with a normal ALT level and low viremia. The strategy is to closely monitor the patients. However, evidence suggests that these group are at risk of gradual disease progression and development of hepatocellular carcinoma. Peginterferon eliminates the hepatitis B virus through immune regulation and induction of antiviral protein expression. For patients with low viral load, the clinical cure rate is potentially promising. In this study, we aim to investigate the efficacy and safety of peginterferon alpha-2b therapy in selected chronic hepatitis B patients with normal ALT level and low viremia. It is expected to obtain a satisfactory curative effect. Peginterferon is a marketed drug available in Chinese clinics with indications of anti-hepatitis B virus.

Details
Condition Chronic Hepatitis B Patients With a Normal ALT Level and Low Viremia
Treatment Peginterferon alpha-2b, Nucleotide Analog, pulse peginterferon alpha-2b
Clinical Study IdentifierNCT05203055
SponsorFuzhou General Hospital
Last Modified on23 March 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

willing to receive the treatment and sign informed consent
18-60 years old (including 18 and 60), both gender
HBsAg positive for at least 6 months and <1500IU/ml
ALT≤1xULN and no elevated ALT has been detected in history
HBV DNA detectable but<2000 IU/ml
HBeAg negative

Exclusion Criteria

For female participants: positive pregnancy test, presently breast-feeding, or unwillingness to use effective contraceptive measures for the duration of the study. For male participants: intent to procreate 3 months before or after the intervention or unwillingness to use effective measures of the contraception
neuropsychiatric diseases, such as depression, anxiety, mania, schizophrenia, or a family history of mental illness (especially with a history of depression or depression tendency)
co-infection of HCV, EBV, other hepatotropic viruses , non-hepatotropic viruses
alcoholic hepatitis, drug-induced hepatitis, autoimmune liver disease
Patients with moderate to severe steatohepatitis
possibility of liver cirrhosis that cannot be excluded
hepatocellular carcinoma or AFP level>30ng/ml
Kidney diseases: acute and chronic nephritis, renal insufficiency, nephrotic syndrome, serum creatinine> 1 x ULN at the time of screening
at screening, the neutrophil count is less than 1.5×10^9/L, and the platelet count is less than 90×10^9/L
Serum phosphorus level <0.7 mmol/L
Antinuclear antibody (ANA)>1:100
Autoimmune diseases, including thyroiditis, psoriasis and systemic lupus erythematosus
Endocrine system diseases, including thyroid diseases and diabetes mellitus
Uncontrolled blood pressure: SBP>160 mmHg or DBP >100 mmHg at the time of enrollment
Evidence of cardiovascular disease, existing congestive cardiac failure on physical exam and/or acute coronary syndrome in the past 6 months
Severe retinopathy or other serious eye diseases
Organic disease or dysfunction
plan to receive an organ transplant or have already undergone an organ transplant
received standardized treatment with interferon or NA products before
allergic to interferon or pharmaceutical excipients, or meet any of the contraindications in the experimental drug instructions
Participated in other interventional trials within 3 months before the screening or other conditions deemed unsuitable by the investigator
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note